* Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the efti group, but not in the placebo group
* The increase in pharmacodynamic markers is significantly linked to improved OS
* Exploratory analysis identified six patient subgroups with improvements in Overall Survival (OS) which are relevant for patient population selection for future late-stage studies
* Five of the six patient subgroups show a statistically significant improvement in OS
For more information, download the attached PDF.
Download this document
